SmartPeptide
Start Free
RecoveryAnimal / preclinical only

TB-500

Synthetic fragment related to thymosin beta-4. Investigated in animal studies for cellular migration and tissue remodeling.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Animal studies suggest cellular migration and tissue remodeling effects, especially in cardiac and dermal wound models.

What's still experimental

Human efficacy is essentially unproven. Safety profile in humans is undocumented in peer-reviewed RCTs.

Anecdotal / community reports

Athletic recovery claims are common in community forums but not supported by published human trials.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “TB-500”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

No established dose range

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

No FDA-approved or established trial dose range for this peptide. Anecdotal ranges discussed in community forums exist but are not supported by published clinical trials, and SmartPeptide will not publish unverified doses.

This is the honest answer for peptides like BPC-157, IGF-1 LR3, MOTS-c, Epitalon and similar research compounds — robust human dose- ranging studies have not been published. Always work with a licensed clinician familiar with experimental peptides if you are considering any use.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
No FDA enforcement actions (recalls, market withdrawals, safety alerts) on record for “TB-500”. This is the expected baseline for most peptides — the absence of recalls does NOT imply general safety, only that no formal FDA enforcement has been initiated against approved formulations.

Mechanism & targets

ChEMBL · UniProt · Open Targets

Molecule (ChEMBL)

View on ChEMBL
Known mechanisms of action
  • CHEMBL3143
    inhibitorCoagulation factor VIII inhibitor

Protein targets (UniProt)

  • Large ribosomal subunit protein bL12m
    P52815gene: MRPL12Homo sapiens· 198 aaReviewed

    As a component of the mitochondrial large ribosomal subunit, plays a role in mitochondrial translation (PubMed:23603806). When present in mitochondria as a free protein not associated with the ribosome, associates with mitochondrial RNA polymerase POLRMT to activate transcription (PubMed:22003127). Required for POLRMT stability (PubMed:26586915)

  • Large ribosomal subunit protein uL30
    Q5SHQ6gene: rpmDThermus thermophilus (strain ATCC 27634 / DSM 579 / HB8)· 60 aaReviewed

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
1,048
total
Human studies
588
MeSH: humans
Clinical trials
8
published
Active trials
2
18 total registered

Recent PubMed studies

Search "thymosin beta-4" on PubMed

Clinical trials (ClinicalTrials.gov)

All trials for "thymosin beta-4"

Europe PMC — 5,068 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
6,104
all years
Last 5 years
2,169
recent activity
Open access
5,519
freely readable
OA share
90%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Total indexed
183,460
all human + lab studies
Meta-analyses
0
highest evidence
Systematic reviews
4
quality-weighted
Clinical trials
0
published RCTs etc.

Most influential human studies

Ranking blends meta-analysis > systematic review > clinical trial weight with influential-citation count and recency. AI TLDRs by Semantic Scholar / Allen Institute for AI.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

NIH-funded research

U.S. National Institutes of Health
Funded projects
194
all years
Top award sum
$18.7M
aggregate USD
Years covered
20
research span
Largest active / recent grants

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
185,892
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • National Natural Science Foundation of China2,323 works
  • National Institutes of Health1,075 works
  • Deutsche Forschungsgemeinschaft411 works
  • National Science Foundation360 works
  • National Research Foundation of Korea344 works
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico277 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 6 of 62 preprints indexed by Europe PMC.

Known risks

Almost no human clinical data. Banned in competitive sport (WADA).

Reported side effects

Limited human safety reporting; theoretical immunomodulation concerns.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
No reports found in the FDA Adverse Event Reporting System for “TB-500”. This is normal for research-only peptides that are not marketed as FDA-approved drugs.

What requires medical supervision

Banned in competitive sport (WADA). Not approved for human use in most countries. Clinical supervision required if used at all.

Questions for your clinician

  • Is there any human safety data we can review?
  • Could this interact with my current medications?
  • What objective markers would we follow if we tried this?

Editorially curated references

Discussions about TB-500

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all TB-500 discussions Native, moderated, no buying or selling